PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

47,725 stories, page 10 of 796

Advanced search
🌍discoverynews.google.comTier 3 · Aggregated media

Ultragenyx Pharmaceutical Inc. (RARE) Seasonal returns chart

Yahoo Finance UKOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Clinuvel Pharmaceuticals Limited (CUV.AX) stock price, news, quote and history

Yahoo Finance AustraliaOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Remibrutinib Phase 3 Results in RMS, Blood Pressure Variability Findings, and Updated Stroke Rehabilitation Guidelines

NeurologyLiveOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Blister Forming Machines Market To 2035: Pharmaceutical Demand Supports Forward Growth - News and Statistics

IndexBoxOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Kymera Therapeutics Earnings Call Highlights Biotech Momentum

TipRanksOriginal source
🌍discoverynews.google.comTier 3 · Aggregated media

Hanmi Pharmaceutical's first glucagon-like peptide-1 (GLP-1)-based obesity treatment "Epeglenatide"

매일경제Original source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Editorial] Sweating the details in exercise oncology

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Corrections] Correction to Lancet Oncol 2025; 26: 898–910

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Comprehensiveness of national cancer control plans

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] The unfulfilled promise of effective cancer medicines priced beyond reach

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Correspondence] BCG-unresponsive non-muscle-invasive bladder cancer – Authors’ reply

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Iberdomide for minimal residual disease-negative myeloma—from underdog to the spotlight

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Correspondence] BCG-unresponsive non-muscle-invasive bladder cancer

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Rare earth elements and the fragile promise of cancer theranostics

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Corrections] Correction to Lancet Oncol 2025; 26: e423–35

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Correspondence] From biomarker actionability to surveillance utility in SERENA-6

Lancet OncologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] From syndrome to antibody-defined autoimmune encephalitides

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[In Context] Learn From Us: stepping into the spotlight after brain injury

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[In Context] Lara M Lange

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[In Context] A Ferrier sesquicentenary

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[In Context] Katrin Andreasson: rethinking neurodegeneration

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Editorial] Neurotrauma as a chronic disease: a call for integrated care

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Correspondence] Staged bilateral focused ultrasound pallidothalamic tractotomy for Parkinson's disease – Authors' reply

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] APOE, p-tau217, and cognitive impairment in diverse cohorts

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Correspondence] Staged bilateral focused ultrasound pallidothalamic tractotomy for Parkinson's disease

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Comment] Progress in exon skipping for Duchenne muscular dystrophy

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[In Context] Climate change: aggravation and adaptation in neurology

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Articles] Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Policy View] Reframing traumatic brain injury and spinal cord injury as chronic multisystem disorders: toward integrated, long-term care

Lancet NeurologyOriginal source
🇺🇰Researchthelancet.comTier 2 · Direct publisher

[Personal View] Antibody-mediated encephalitides: distinct diseases with transdisciplinary implications

Lancet NeurologyOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

眼瞼下垂をテーマにしたプレスセミナーを開催

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

令和8年熊本地震に対する義援金の寄付について

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

サステナビリティレポート2026を発行

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

当社名をかたるSNSなりすましアカウントに関する注意喚起

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

「健康経営優良法人2026（大規模法人部門）」に認定

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

近視の進行抑制を目的とする点眼剤STN1012700（Ryjusea 0.25mg/mL点眼液）の販売承認を韓国で取得

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

一部製品の価格改定に関するご案内

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

統合報告書「Santen Report 2026」を発行

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

Advanced Vision Science社の譲渡について

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

近視の進行抑制を目的とする点眼剤STN1012700（アトロピン硫酸塩点眼液0.025％）の中国における承認申請が受理

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

緑内障・高眼圧症治療剤「ロープレッサ®点眼液0.02%」発売のお知らせ

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

世界初開催の「Global Summit for Eye Health」にHigh Impact Partnerとして参画

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

アレルギー性結膜炎治療剤「アレジオン®眼瞼クリーム0.5%」参天製薬と杏林製薬の日本における共同販売促進契約締結のお知らせ

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

近視の進行抑制を目的とする点眼剤STN1012700（Ryjusea 0.25mg/mL点眼液）についてアジア事業地域で初めてとなる販売承認をフィリピンで取得

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

緑内障・高眼圧症治療剤「ロープレッサ®点眼液0.02%」国内における製造販売承認を取得

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

「ちびまる子ちゃん」と考える、子どもの近視 ― 日常の気づきから“まずは眼科へ”を伝える疾患啓発メッセージを全国に展開 ―

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

Santen中国、5つの緑内障点眼薬について、中国本土における独占的な流通および販売促進に関する契約を締結

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

後天性眼瞼下垂治療剤「アップニーク®ミニ点眼液0.1%」発売のお知らせ

Santen Pharmaceutical NewsOriginal source
🇯🇵Industrysanten.comTier 1 · Company source

役員人事に関するお知らせ

Santen Pharmaceutical NewsOriginal source
🇺🇸Researchonlinejcf.comTier 2 · Direct publisher

Updated Staging System to Define Cardiogenic Shock Severity A Cardiogenic Shock Working Group Report

Journal of Cardiac FailureOriginal source
🇯🇵Industrykifu-shinsei.jpTier 3 · Secondary coverage

「2026年度 参天製薬奨学寄付プログラム」の募集は終了しました

Santen Pharmaceutical NewsOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Janus Kinase Inhibitor Use Among People With Inflammatory Disease in Australia.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Response to correspondence on 'Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)'.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Estimation of Treatment Effect in Clinical Trials of Continuous Endpoints With Retrieved Dropouts.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Rare and Novel Hepatitis C Virus Genotype Subtypes and Response to Sofosbuvir/Velpatasvir in A5360 (MINMON) Clinical Trial.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Stereoselective Determination of Omeprazole and 5-Hydroxy-Omeprazole in Dried Blood Spots for CYP2C19 Activity Assessment.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Unified Implementation and Comparison of Bayesian Shrinkage Methods for Treatment Effect Estimation in Subgroups.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Landscape Analysis of Digital Health Technology Use for Remote Data Acquisition in CDER-Regulated Submissions, 2023-2025.

Europe PMCOriginal source
🇪🇺Researcheuropepmc.orgTier 2 · Direct publisher

Target Trial Emulation or Target Trial Approximation?

Europe PMCOriginal source